UBS O'Connor’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $506K | Sell |
37,891
-77,627
| -67% | -$1.04M | 0.03% | 247 |
|
|
2025
Q1 | $1.18M | Buy |
115,518
+64,621
| +127% | +$658K | 0.04% | 159 |
|
|
2024
Q4 | $806K | Buy |
50,897
+26,145
| +106% | +$414K | 0.02% | 243 |
|
|
2024
Q3 | $1.44M | Buy |
24,752
+2,299
| +10% | +$134K | 0.04% | 226 |
|
|
2024
Q2 | $1.03M | Buy |
22,453
+5,400
| +32% | +$247K | 0.03% | 288 |
|
|
2024
Q1 | $1.13M | Buy |
17,053
+2,941
| +21% | +$195K | 0.03% | 259 |
|
|
2023
Q4 | $561K | Sell |
14,112
-46,229
| -77% | -$1.84M | 0.02% | 329 |
|
|
2023
Q3 | $1.92M | Buy |
60,341
+5,000
| +9% | +$159K | 0.03% | 249 |
|
|
2023
Q2 | $2.22M | Buy |
55,341
+9,857
| +22% | +$396K | 0.05% | 274 |
|
|
2023
Q1 | $1.94M | Buy |
+45,484
| New | +$1.94M | 0.05% | 318 |
|
|
2022
Q4 | – | Sell |
-33,321
| Closed | -$1.25M | – | 171 |
|
|
2022
Q3 | $1.25M | Sell |
33,321
-24,000
| -42% | -$903K | 0.01% | 709 |
|
|
2022
Q2 | $1.58M | Buy |
+57,321
| New | +$1.58M | 0.02% | 691 |
|